On June 18, 2025, the FDA approved Gilead’s Yeztugo (lenacapavir) for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired human immunodeficiency virus type 1 (HIV-1). Yeztugo is the first FDA-approved, twice-yearly, subcutaneous PrEP option for HIV prevention. Gilead has announced that the list price for Yeztugo will be...
The glucagon-like peptide-1 (GLP-1) drug class is expected to continue to expand in both the indications the class treats as well as the number of GLP-1 medications brought to market.
Several GLP-1 medications could receive FDA approval to expand the indications they are approved for by the end of 2025, this includes ...
Recently, two studies published in the Journal of The American Medical Association investigated the return on investment associated with coverage of GLP-1 agonists in the treatment of obesity. The study titled “Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity” evaluated ...
On April 16, 2025, the Department of Commerce announced that it had initiated an investigation into the effects pharmaceutical ingredients and products have on national security. The Department’s investigation is likely to focus on several ...
On April 15, 2025, President Trump issued an Executive Order (EO) titled “Lowering Drug Prices by Once Again Putting America First”, introducing several concepts aimed at lowering the cost of prescription medications in the United States...
